CBA Florida Inc. (fka CBAI)

[Dew]

LAS VEGAS, April 19, 2010 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that it has signed a Letter of Intent to purchase controlling interest in BioCells, Inc., headquartered in Argentina, with affiliates under development in Peru, Colombia, Bolivia, Panama and Puerto Rico.
BioCells, the second largest stem cell storage company in Argentina, is profitable, with annual revenues in 2009 of $1.2 million (USD), and 12 locations throughout that country, plus recent expansion into Uruguay and Paraguay. On February 8, 2010, Cord Blood America announced that BioCells finalized an agreement to process and store cord blood specimens with Cord Blood America in Las Vegas.

"The transaction is subject to the normal due diligence process," said Matthew Schissler, Cord Blood America co-founder and CEO. "We believe this potential transaction is an excellent example of how we are building Cord Blood America into the world's premier stem cell storage company. If successful in due diligence, this will give CBAI a majority stake in a proven South American company. Adding our recently announced acquisition in Europe and our Licensing Agreement in China, this step further proves our commitment to our mission, becoming the world's largest stem cell storage company and creating the cellular pharmacy business model which will be in high demand in years to come."